

## **LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE**

**Bottle of 500 ml (PET)**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

AquaVac PD3 emulsion for injection for Atlantic salmon

**2. STATEMENT OF ACTIVE SUBSTANCES**

Per dose of 0.1 ml vaccine:

Salmon pancreas disease virus (SPDV)  $\geq 75\%$  RPP

Infectious pancreatic necrosis virus (IPNV)  $\geq 1.5$  ELISA units

*Aeromonas salmonicida* subsp. *salmonicida*  $\geq 80\%$  RPS<sub>60</sub>

Light liquid paraffin, 43 mg

**3. PHARMACEUTICAL FORM**

Emulsion for injection.

**4. PACKAGE SIZE**

500 ml (5,000 doses)

**5. TARGET SPECIES**

Atlantic salmon.

**6. INDICATION(S)**

Vaccine against pancreas disease, infectious pancreatic necrosis and furunculosis.

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.

Intraperitoneal use.

**8. WITHDRAWAL PERIOD(S)**

Withdrawal period(s): Zero degree days.

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use.

Accidental injection is dangerous.

**10. EXPIRY DATE**

EXP {month/year}

Once broached, use within 1 working day.

**11. SPECIAL STORAGE CONDITIONS**

Store in a refrigerator.

Do not freeze.

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Disposal: Read package leaflet.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only.

To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

MSD Animal Health UK Ltd.  
Walton Manor  
Walton  
Milton Keynes  
MK7 7AJ

**16. MARKETING AUTHORISATION NUMBER**

Vm 01708/5108

**17. MANUFACTURER'S BATCH NUMBER**

Batch {number}

## **B. PACKAGE LEAFLET**

**PACKAGE LEAFLET:**  
**AquaVac PD3 emulsion for injection for Atlantic salmon**

**1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Marketing authorisation holder:

MSD Animal Health UK Ltd.  
Walton Manor  
Walton  
Milton Keynes  
Buckinghamshire  
MK7 7AJ

Manufacturer responsible for batch release:

Intervet International B.V.  
Wim de Körverstraat 35  
5831 AN Boxmeer  
The Netherlands

**2. NAME OF THE VETERINARY MEDICINAL PRODUCT**

AquaVac PD3 emulsion for injection for Atlantic salmon

**3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)**

Per dose of 0.1 ml vaccine:

Active substances:

Salmon pancreas disease virus (SPDV) strain F93-125  $\geq 75\%$  RPP<sup>1</sup>  
Infectious pancreatic necrosis virus (IPNV)  $\geq 1.5$  ELISA units<sup>2</sup>  
*Aeromonas salmonicida* subsp. *salmonicida*  $\geq 80\%$  RPS<sub>60</sub><sup>3</sup>

Light liquid paraffin, 43 mg

<sup>1</sup> RPP: relative percentage protection in a laboratory test in Atlantic salmon

<sup>2</sup> Antigenic mass measured in the final product

<sup>3</sup> RPS: relative percentage survival at 60% control mortality in a laboratory test in Atlantic salmon

Emulsion for injection.

**4. INDICATION(S)**

For active immunisation of Atlantic salmon to reduce clinical signs (heart lesions and pancreas lesions), viremia, viral shedding and mortality from infection with SPDV

(Pancreas disease) and to reduce mortality from infections with IPNV (Infectious pancreatic necrosis) and *Aeromonas salmonicida* subsp. *salmonicida* (furunculosis).

Onset of immunity: 500 degree days after vaccination for SPDV and *Aeromonas salmonicida* and 540 degree days after vaccination for IPNV.

Duration of immunity: demonstrated at 15 months post vaccination for SPDV and at 16 months post vaccination for *Aeromonas salmonicida*. Protection against mortality due to IPNV infection has been demonstrated at 4 months post vaccination in the field.

## **5. CONTRAINDICATIONS**

None.

## **6. ADVERSE REACTIONS**

After vaccination melanisation and vaccine residues are very commonly observed in the abdominal cavity. Visceral adhesion may be observed; during the fresh water phase up to sea transfer phase slight to moderate adhesions (corresponding to Speilberg scores 1 – 3) very commonly occur while the occurrence of major adhesions (corresponding to Speilberg score of 4) is uncommon.

During the sea water phase mild adhesions (corresponding to Speilberg scores 1 – 2) are very common and moderate adhesions (corresponding to Speilberg scores 3) are common.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reactions)
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

## **7. TARGET SPECIES**

Atlantic salmon (*Salmo salar* L).

## **8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION**

Dose: 0.1 ml per fish.

Route of administration: intraperitoneal injection in Atlantic salmon. Correct site of injection is along the central line, approximately 1 pelvic fin length in front of the pelvic fin base. Shake the bottle well before use.



## **9. ADVICE ON CORRECT ADMINISTRATION**

Vaccination is recommended for fish above 30 grams.  
Food should be withheld for sufficient time (at least 48 hours) to ensure emptying of the gut prior to vaccination. The fish should be anaesthetised before vaccination. The length and the diameter of the applied needle should be adapted to the actual fish size. Ensure that the recommended dose is deposited into the abdominal cavity before the needle is withdrawn.

## **10. WITHDRAWAL PERIOD(S)**

Zero degree days.

## **11. SPECIAL STORAGE PRECAUTIONS**

Keep out of the sight and reach of children.  
Store in a refrigerator (2 °C – 8 °C).  
Do not freeze.  
Do not use this veterinary medicinal product after the expiry date which is stated on the label.  
Shelf life after first opening the container: use within 1 working day.

## **12. SPECIAL WARNING(S)**

Special warnings for each target species:  
Vaccinate healthy animals only.

Special precautions for use in animals:  
Do not use in fish during smoltification.  
Incorrect vaccination, stress and poor hygiene may lead to increased side effects.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Personal protective equipment consisting of e.g. needle protector should be used when handling the product.  
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or label to the physician.

To the user:

This veterinary medicinal product contains mineral oil. Accidental injection/self-injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given.

If you are accidentally injected with this product, seek prompt medical advice even if only a very small amount is injected and take the package leaflet with you.

If pain persists for more than 12 hours after medical examination, seek medical advice again.

To the physician:

This veterinary medicinal product contains mineral oil. Even if small amounts have been injected, accidental injection with this product can cause intense swelling, which may, for example, result in ischaemic necrosis and even the loss of a digit. Expert, PROMPT, surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.

Fertility:

Do not use in broodstock. The possible effects of vaccination on spawning have not been investigated.

Interaction with other medicinal products and other forms of interaction:

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

Overdose (symptoms, emergency procedures, antidotes):

After administration of a double dose more vaccine residues can be observed, but no increase in local reactions is observed compared to single dose administration.

Incompatibilities:

Do not mix with any other veterinary medicinal product.

### **13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**


Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

### **14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

August 2020

### **15. OTHER INFORMATION**

Pack size: 500 ml (5,000 doses)



Approved: 10 October 2023